Cervical cancer (CC) is a main malignancy affecting women globally, with a high mortality rate. Chemoradiotherapy resistance is a significant factor in determining treatment outcomes, and prognostic biomarkers are essential for the appropriate selection of therapeutic strategies. This study aimed to identify gene expression signatures that may allow for follow‐up treatment response in CC patients.
Angelo Borges de Melo, F. Queiroz, Carolina Pereira de Souza Melo et al.· Cancer Medicine· 0 citations
As new SARS-CoV-2 subvariants emerge alongside continuous reports of post-acute long-term sequelae after COVID-19, there is an urgent need to mitigate the harmful effects associated with SARS-CoV-2 infection. While antiviral protection is commonly assessed by measuring neutralizing antibodies, specific antiviral CD8+ T cell responses are also relevant for long-term immunity. In this context, tools that improve our knowledge regarding anti-SARS-CoV-2 CD8+ T cell immunity are important for monitoring antiviral responses, supporting the development of new approaches to induce long-term immunity. Here, we sought to establish a cost-effective platform that enables the direct identification of SARS-CoV-2 peptide-reactive CD8+ T cells restricted to HLA-A*02, a highly frequent allele family in the Brazilian population. For this, we produced an HLA-A*02 dimeric molecule (HLA-A*02:01-IgG) in-house, coupled with peptides derived from SARS-CoV-2, and used in flow cytometry assays to identify antigen-specific CD8+ T cell populations. Using low concentrations of HLA-A*02:IgG-peptide complex (0.25 μg/mL), we were able to detect anti-SARS-CoV-2-specific CD8+ T cells in HLA-A*02-positive individuals, but not in HLA-A*02-negative individuals, as expected. Furthermore, ROC curve analysis showed maximum sensitivity and specificity (100%, AUC = 1.0), highlighting the effectiveness of our method Overall, our assay identified virus-specific CD8+ T cell populations in HLA-A*02 individuals using low concentrations of HLA-A*02:IgG-peptide complex, supporting its use to evaluate the CD8+ T cell responses restricted to SARS-CoV-2. This method may provide insights into cellular immunity in the context of the current vaccination and help guide new vaccine and/or therapeutic platform development, including the analysis of memory CD8+ T cell subsets.
Á. Lopes-Ribeiro, T. A. Pereira-Santos, Maria Eduarda Martuchele Félix et al.· JIM - Journal of Immunologic...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
